Merck Simplifies And Streamlines Method Development With In Silico Modeling

As analytical demands increase across biopharmaceutical development, efficiency in method development has become a competitive necessity. Growing molecular diversity, tighter timelines, and heightened expectations for robustness are pushing teams to move beyond traditional trial‑and‑error workflows. This real‑world example from Merck highlights how combining automated chromatographic screening with advanced in silico modeling can fundamentally reshape analytical strategies. By pairing multicolumn screening with computer‑assisted simulation, scientists reduced hands‑on experimentation while gaining deeper insight into separation behavior early in development. The approach delivered consistent success across ion exchange, reverse phase, and chiral UHPLC applications, producing reliable methods in significantly less time. Strong alignment between experimental outcomes and simulated predictions reinforced confidence in modeling‑driven decisions.

For organizations seeking to scale analytical rigor without slowing development, access the full case study to learn more.